FGFR2 and gastric cancer: In the randomized, double-blind, placebo-controlled phase II FIGHT trial, GC and EJC patients with FGFR2b overexpression (by IHC) or FGFR2 gene amplification (by ctDNA evaluation) received either bemarituzumab or placebo in combination with modified FOLFOX6 (mFOLFOX6) chemotherapy.